Serum Levels of Infliximab Biosimilar in a Child Delivered From a Mother Treated for Ulcerative Colitis

Ami Kawamoto; Toshimitsu Fujii; Ryuji Mitani; Yasuhiro Suzuki; Tsunehito Yauchi; Ryuichi Okamoto

doi:10.1093/ibd/izac111

Serum Levels of Infliximab Biosimilar in a Child Delivered From a Mother Treated for Ulcerative Colitis

Inflamm Bowel Dis. 2022 Aug 1;28(8):1298-1299. doi: 10.1093/ibd/izac111.

Authors

Ami Kawamoto¹, Toshimitsu Fujii^{1

2}, Ryuji Mitani³, Yasuhiro Suzuki⁴, Tsunehito Yauchi², Ryuichi Okamoto¹

Affiliations

¹ Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
² Department of Gastroenterology, Soka Municipal Hospital, Soka City, Japan.
³ Department of Obstetrics and Gynecology, Yoshinogawa Medical Center, Yoshinogawa City, Japan.
⁴ Department of Gastroenterology, Tokushima Prefectural Central Hospital, Tokushima City, Japan.

PMID: 35700275
DOI: 10.1093/ibd/izac111

No abstract available

Keywords: biosimilar; pregnancy; ulcerative colitis.

Plain language summary

The infliximab biosimilar CT-P13 is used for the treatment of ulcerative colitis. We report for the first time the serum drug levels and long-term health status of the child of a patient treated with CT-P13 throughout her pregnancy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biosimilar Pharmaceuticals* / therapeutic use
Child
Colitis, Ulcerative* / drug therapy
Female
Gastrointestinal Agents / therapeutic use
Humans
Inflammatory Bowel Diseases* / drug therapy
Infliximab / therapeutic use
Mothers
Treatment Outcome

Substances

Biosimilar Pharmaceuticals
Gastrointestinal Agents
Infliximab